ReviewCA: a cancer journal for clinicians2013
Recent progress in pancreatic cancer.
Review in CA: a cancer journal for clinicians, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 499 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
499 citing papers in PubMed, 8 syntheses or guidelines pooled it, 934 citations in OpenAlex.
- Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer.Scientific reports · 2026Pooled it
- Diagnostic value of integrating salivary and blood miRNAs for pancreatic cancer detection.Frontiers in oncology · 2025Pooled it
- Body composition as a predictor of chemotherapy-related toxicity in pancreatic cancer patients: A systematic review.Frontiers in oncology · 2022Pooled it
- Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review.Cell communication and signaling : CCS · 2021Pooled it
- Pooled it
- Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis.Aging · 2020Pooled it
- Pooled it
- Physical function in patients with resectable cancer of the pancreas and liver-a systematic review.Journal of cancer survivorship : research and practice · 2020Pooled it
- Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017.Cancer letters · 2021Trial
- The Landmark Series: Mutation-Based Therapy of Pancreatic Cancer.Annals of surgical oncology · 2026Review
- The Advanced Lung Cancer Inflammation Index Is Not Independently Prognostic for Overall Survival in De Novo Metastatic Pancreatic Cancer: A Comparison with Established Inflammation- and Nutrition-based Scores.Journal of gastrointestinal cancer · 2026Article
- Nintedanib inhibits the VEGFR-ERK signaling pathway in human KRAS-mutated cancer cells.Cell death & disease · 2026Article
- CXCR2 blockade overcomes the NETosis-mediated resistance to MEK inhibition in pancreatic cancer models.The Journal of clinical investigation · 2026Article
- Pyrazole-Cyclotriphosphazene Hybrids: Synthesis, Structural Insights, and Cytotoxic Effects against Pancreatic Cancer Cells.ACS omega · 2026Article
- Oncolytic adenovirus in combination with PD-L1-targeted radioimmunotherapy exerts synergistic antitumor effect against pancreatic cancer.Journal for immunotherapy of cancer · 2026Article
- Tridax procumbens promotes apoptosis and suppresses markers of proliferation, growth, and metastasis in pancreatic ductal adenocarcinoma cells.BMC complementary medicine and therapies · 2026Article
- Markers of immune activation and immunotherapy responsiveness are increased in 3D Pancreatic cancer organoids when primed with photodynamic- and chemo-therapy.Translational oncology · 2026Article
- Toward Timely Diagnosis of Pancreatic Cancer: Revolutionizing Early Detection Through Genomics, Artificial Intelligence, and Noninvasive Biomarkers.Journal of gastroenterology and hepatology · 2026Review
- Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the "Undruggable" Paradigm.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Review
- Analysis of prognostic factors for advanced pancreatic neuroendocrine carcinoma: A population-based study.Medicine · 2026Article
439 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Pancreatic cancer is currently one of the deadliest of the solid malignancies. However, surgery to resect neoplasms of the pancreas is safer and less invasive than ever, novel drug combinations have been shown to improve survival, advances in radiation therapy have resulted in less toxicity, and enormous strides have been made in the understanding of the fundamental genetics of pancreatic cancer. These advances provide hope but they also increase the complexity of caring for patients. It is clear that multidisciplinary care that provides comprehensive and coordinated evaluation and treatment is the most effective way to manage patients with pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.